PE Biosystems (PEB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PE Biosystems (PEB)

PEB 11.49

0.0%

Dec 29 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: Mel Spivak who started this subject	9/4/2000 9:50:56 AM
From: nigel bates	of 122

Sept. 4 /PRNewswire/ -- Amersham Pharmacia Biotech, the life sciences business of Nycomed Amersham, plc (NYSE: NYE - news; LSE: NAM), announced today that it has won a patent infringement case against PerSeptive, a part of PE Corporation. The United States Court of Appeals for the Federal Circuit found in favour of Amersham Pharmacia Biotech and held that the so-called 'perfusion chromatography' patents assigned to PerSeptive Biosystems are unenforceable. The case began in 1993 when Pharmacia filed suit against PerSeptive to protect Pharmacia's commercial position. The chromatography product related to the patent dispute -- SOURCE(TM) -- is used for separation of biomolecules on an industrial scale. The appeals court affirmed the earlier findings of the United States District Court for the District of Massachusetts, which had concluded that the patents were procured by PerSeptive through inequitable conduct.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext